Concepedia
Statistics
Publications
31
Citations
3.2K
H-Index
23
Active since
1994
Affiliations
Seagen (United States)(Current)
University of Washington
Robert P. Lyon is an author at Seagen (United States) specializing in medicine, pharmacology, and drug discovery.
Top concepts
MedicinePharmacologyDrug DiscoveryAntibody EngineeringImmunologyBiochemistryNatural SciencesImmunotherapyBiomolecular EngineeringChemical Biology
Publications per year
1994–2023
Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
Robert P. Lyon, Tim D. Bovee, Svetlana O. Doronina et al. · Nature Biotechnology · 2015 · 498 citations
Medicinal Chemistry, Polymer-drug Conjugate, Medicine +8
Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates
Robert P. Lyon, Jocelyn R. Setter, Tim D. Bovee et al. · Nature Biotechnology · 2014 · 430 citations
Pharmaceutical Science, Biochemistry, Polymer-drug Conjugate +9
SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
May S.K. Sutherland, Roland B. Walter, Scott C. Jeffrey et al. · Blood · 2013 · 381 citations
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
Li Fu, Kim K. Emmerton, Mechthild Jonas et al. · Cancer Research · 2016 · 302 citations
Immunology, Immunotherapy, Tumor Biology +16
A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology
Scott C. Jeffrey, Patrick Burke, Robert P. Lyon et al. · Bioconjugate Chemistry · 2013 · 241 citations
Drug Target, Immunology, Molecular Biology +21
1–5 of 31